Latest Innovation News

Orbital Corporation reports a $0.5 million operating cash outflow for Q2 2025, while progressing development of a larger UAV engine now entering customer flight trials.

RemSense Technologies closed FY2025 with a positive EBITDA and expanding virtualplant platform usage among major clients, setting the stage for significant growth in FY2026. The company’s strategic hires and new contracts highlight its rising footprint in industrial digital transformation.

Energy Action Ltd reports a robust Q4 FY25 with significant revenue growth, sustained positive cash flow, and strategic refinancing, while advancing its AI-driven Utilibox platform and zero-carbon solutions.

Jindalee Lithium progresses its McDermitt Lithium Project with strong US government support and a promising new refining technology partnership, aiming to enhance sustainability and reduce costs.

Activeport Group has rapidly expanded its Network-as-a-Service platform, securing $3.2 million in contracts within two months of launch, signaling strong market demand for flexible fibre connectivity solutions.

Environmental Clean Technologies Limited has secured crucial regulatory approvals for its Bacchus Marsh fertiliser facility and completed a $275K capital raise, while deferring field trials to better align with cropping cycles. The company is also undergoing significant restructuring to improve capital efficiency and focus on strategic growth.

Cambium Bio has raised A$2.12 million through a fully subscribed placement led by Taiwanese institutional investor Da Jyun Capital, supporting the initiation of pivotal Phase 3 trials for its lead ophthalmology candidate.

Reward Minerals Limited is progressing its innovative potash processing technologies while simultaneously advancing exploration of its 100% owned Kalgoorlie gold projects, supported by a solid cash position of $1.738 million.

Platina Resources reported steady progress across multiple Western Australian gold projects in the June 2025 quarter, balancing promising drill results with operational hurdles and a solid cash position.

Jatcorp Limited reported a robust 76% revenue increase in Q4 FY25, driven by strong Moroka® sales and expanded manufacturing capabilities, setting ambitious growth targets for FY26.

Alterity Therapeutics has secured U.S. FDA Fast Track designation for its drug ATH434 targeting Multiple System Atrophy, supported by promising Phase 2 clinical trial data showing slowed disease progression and a solid safety profile.

Uscom Limited reported a significant revenue decline in Q4 2025 amid global market instability but is focusing on cost management and strategic partnerships to position for recovery.